Cas:62031-54-3 Fibroblast Growth Factor manufacturer & supplier

Chemical Name:Fibroblast Growth Factor

CAS.NO:62031-54-3

Synonyms:MFCD00133317;L-Prolyl-L-alanyl-L-leucyl-L-prolyl-L-α-glutamyl-L-α-aspartylglycylglycyl-L-serylglycyl-L-alanyl-L-phenylalanyl-L-prolyl-L-prolylglycyl-L-histidyl-L-phenylalanyl-L-lysyl-L-α-aspartyl-L-pro
 lyl-L-lysyl-L-arginyl-L-leucyl-L-tyrosine;L-Tyrosine, L-prolyl-L-alanyl-L-leucyl-L-prolyl-L-α-glutamyl-L-α-aspartylglycylglycyl-L-serylglycyl-L-alanyl-L-phenylalanyl-L-prolyl-L-prolylglycyl-L-histidyl-L-phenylalanyl-L-lysyl-L-α-as
 partyl-L-prolyl-L-lysyl-L-arginyl-L-leucyl-

Molecular Formula:C₆₂H₉₅N₁₅O₁₅

Molecular Weight:1290.51

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.5±0.1 g/cm3

Index of Refraction:1.682

PSA:

Exact Mass:2552.281250

LogP:-0.13

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like MFCD00133317 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,partyl-L-prolyl-L-lysyl-L-arginyl-L-leucyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,lyl-L-lysyl-L-arginyl-L-leucyl-L-tyrosine Use and application,lyl-L-lysyl-L-arginyl-L-leucyl-L-tyrosine technical grade,usp/ep/jp grade.

Related News: Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit bromo(N-tert-butylbenzenesulfenamido)bis(pentamethylcyclopentadienyl)uranium(IV) manufacturers One of the main benefits of biocatalysis is that it increases conversion efficiency for significantly higher yields with fewer by-products, equating to faster and more cost-effective production. 3-benzyl-2-morpholinoquinolin-4-amine suppliers As the Covid-19 pandemic continues to challenge the global drug supply chain, nations are looking for new ways to enable native producers to continue scaling up. Now, an Israeli API maker is dropping a down payment into an Indian intermediates company to ramp up its own manufacturing base. N-Acetyl-4a,9b-(4-methylphenylenedioxy)-1,2,3,4,4a,9b-hexahydrocarbazole vendor & factory.